References
- Roughhead L, Semple S, Rosenfeld E. Literature Review: medication safety in Australia (2013). Australian Commission on Safety and Quality in Health Care, Sydney. Available from: https://www.safetyandquality.gov.au/sites/default/files/migrated/Literature-Review-Medication-Safety-in-Australia-2013.pdf
- Page AT, Falster MO, Litchfield M, et al. Polypharmacy among older Australians, 2006–2017: a population‐based study. Med J Aust. 2019;211:71–75.
- Schaumberg DA, Dana R, Buring JE, et al. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009;127:763–768.
- Oshika T. Ocular adverse effects of neuropsychiatric agents: incidence and management. Drug Saf. 1995;12:256–263.
- Siddall JR. Ocular toxic changes associated with chlorpromazine and thioridazine. Can J Ophthalmol. 1966;1:190–198.
- Hird TR, Zomer E, Owen AJ, et al. Productivity Burden of Hypertension in Australia. Hypertension. 2019;73:777–784.
- Klabune RE. Cardiovascular Physiology Concepts. Available from: https://www.cvphysiology.com
- Bartlett JD. Ophthalmic toxicity by systemic drugs. In: Chiou GCY, editor. Ophthalmic Toxicology. Vol. 2. Michigan: Taylor and Francis; 1999. pp. 225–283.
- Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, et al. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by Bevacizumab. Retina. 2013;33:508–512.
- Traband A, Shaffer JA, VanderBeek BL. Systemic beta-blockers in neovascular age-related macular degeneration. Retina. 2017;37:41–46.
- Kolomeyer AM, Maguire MG, Pan WMS, et al. Systemic beta-blockers and risk of progression to neovascular age-related macular degeneration. Retina. 2019;39:918–925.
- Kaiser HJ, Flammer J, Graf T, et al. Systemic blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 1993;231:677–680.
- Horwitz A, Klemp M, Jeppesen J, et al. Antihypertensive medications postpones the onset of glaucoma. Hypertension. 2017;69:202–210.
- Iskedjian M, Walker JH, Desjardins O, et al. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study. Curr Med Res Opin. 2009;25:1879–1888.
- Flammer J, Konieczka K, Bruno RM, et al. The eye and the heart. Eur Heart J. 2013;34:1270–1278.
- Müskens RP, de Voogd S, Wolfs RC, et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmol. 2007;114:2221–2226.
- Miglior S, Torri V, Zeyen T, et al. EGPS Group. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol. 2007;144:266–275.
- Deb AK, Kaliaperumal S, Rao VA, et al. Relationship between systemic hypertension, perfusion pressure and glaucoma: a comparative study in an adult Indian population. Indian J Ophthalmol. 2014;62:917–922.
- Zimmet P, Alberti KG, Magliano DJ, et al. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016;12:616–622.
- Microdata: National Health Survey. Findings based on Detailed Microdata File analysis. Canberra: ABS; 2017-2018. Available from: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey-first-results/latest-release
- Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care. 2005;28:1599–1603.
- DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194.
- Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740–751.
- Metformin. Federal Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021748s002lbl.pdf
- Medication for type 2 diabetes. Living with Diabetes. Diabetes Australia; 2020. Available from: https://www.diabetesaustralia.com.au/living-with-diabetes/medicine/tablets/
- Attebo K, Ivers RQ, Mitchell P. Refractive errors in an older population: the Blue Mountains Eye Study. Ophthalmol. 1999;106:1066–1072.
- Wang Q, Klein BE, Klein R, et al. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 1994;35:4344–4347.
- Sonmez B, Bozkurt B, Atmaca A, et al. Effect of glycemic control on refractive changes in diabetic patients with hyperglycemia. Cornea. 2005;24:531–537.
- Okamoto F, Sone H, Nonoyama T, et al. Refractive changes in diabetic patients during intensive glycaemic control. Br J Ophthalmol. 2000;84:1097–1102.
- Lin HC, Stein JD, Nan B, et al. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 2015;133:915–923.
- Maleškić S, Kusturica J, Gušić E, et al. Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes - observational study. Acta Med Acad. 2017;46:116–123.
- Top. 10 drugs 2018–19. Aust Prescr. 2019;42:204.
- Ofori-Asenso R, Ilomaki J, Zomer E, et al. A 10-Year trend in statin use among older adults in Australia: an analysis using national pharmacy claims data. Cardiovasc Drugs Ther. 2018;32:265–272.
- Adedinsewo D, Taka N, Agasthi P, et al. Prevalence and factors associated with statin use among a nationally representative sample of US adults: national Health and Nutrition Examination Survey, 2011-2012. Clin Cardiol. 2016;39:491–496.
- Stancu C, Anca S. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–387.
- Negveskey G, Kolsky M, Laureano R, et al. Reversible atorvastatin-associated external ophthalmoplegia, anti acetylcholine receptor antibodies, and ataxia. Arch Ophthalmol. 2000;118:427–428.
- Ertas F, Ertas N, Gulec S, et al. Unrecognized side effect of statin treatment: unilateral blepharoptosis. Ophthalmic Plast Reconstr Surg. 2006;22:222–224.
- Finsterer J, Zuntner G. Rhabdomyolysis from simvastatin triggered by infection and muscle exertion. South Med J. 2005;98:827–829.
- Stein J, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves’ disease. JAMA Ophthalmol. 2015;133:290.
- Ooi K, Wakefield D, Billson F, et al. Efficacy and safety of topical atorvastatin for the treatment of dry eye associated with blepharitis: a pilot study. Ophthalmic Res. 2015;54:26–33.
- Ooi K, Lee M, Burlutsky G, et al. Association of dyslipidaemia and oral statin use, and dry eye disease symptoms in the Blue Mountain Eye Study. Clin Exp Ophthalmol. 2018;47:187–192.
- Kostis J, Dobrzynski J. Prevention of cataracts by statins: a meta-analysis. J Cardiovasc Pharmacol Ther. 2014;19:191–200.
- Leuschen J, Mortensen E, Frei C, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131:1427–1434.
- Marcus M, Muskens R, Ramadas W, et al. Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS ONE. 2012;7:e29724.
- Kang J, Boumenna T, Stein J, et al. Association of statin use and high serum cholesterol levels with risk of primary open angle glaucoma. JAMA Ophthalmol. 2019;137:756–765.
- Keech A, Mitchell P, Summanen PA, et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet. 2007;370:1687–1697.
- Chew E, Ambrosius W, Davis M, et al. ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in Type 2 diabetes. N Engl J Med. 2010;363:233–244.
- Australian public assessment report for fenofibrate. Therapeutic Goods Administration, 2014. Available from: https://www.tga.gov.au/file/6794/download
- Kang EY-C, Chen T, Gary S, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2019;137:363–371.
- Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58–63.
- Rajeshuni N, Ludwig CA, Moshfeghi DM. The effect of statin exposure on choroidal neovascularization in nonexudative age-related macular degeneration patients. Eye. 2019;33:163–165.
- National survey of mental health and wellbeing: summary of results, Australia, 2007. Australian Bureau of Statistics, 2008. Available from: https://www.abs.gov.au/statistics/health/mental-health/national-survey-mental-health-and-wellbeing-summary-results/latest-release
- Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma: assessment and appropriate precautions. Psychosomatics. 1987;28:145–148.
- Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol. 2001;119:1210–1211.
- Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull. 1997;23:567–582.
- Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacol (Berl). 1986;88:403–419.
- Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13:S362–8.
- Stapleton JM, Guthrie S, Linnoila M. Effects of alcohol and other psychotropic drugs on eye movements: relevance to traffic safety. J Stud Alcohol. 1986;47:426–432.
- Bittencourt PRM, Wade P, Smith AT, et al. Benzodiazepines impair smooth pursuit eye movements. Br J Clin Pharmacol. 1983;15:259–262.
- Young YH, Huang TW. Role of clonazepam in the treatment of idiopathic downbeat nystagmus. Laryngoscope. 2001;111:1490–1493.
- Williams DP, Troost BT, Rogers J. Lithium-induced downbeat nystagmus. Arch Neurol. 1988;45:1022–1023.
- Jørgensen JS, Landschoff Lassen L, Wegener M. Lithium-induced downbeat nystagmus and horizontal gaze palsy. Open Ophthalmol J. 2016;10:126–128.
- Schein F, Manoli P, Cathébras P. Lithium-induced downbeat nystagmus. Am J Ophthalmol. 2017;7:74–75.
- Chrousos GA, Cowdry R, Schuelein M, et al. Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine. Am J Ophthalmol. 1987;103:221–224.
- Malone DA Jr, Camara EG, Krug JH. Jr. Ophthalmologic effects of psychotropic medications. Psychosomatics. 1992;33:271–277.
- Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111:1275–1279.
- Johnson AW, Buffaloe WJ. Chlorpromazine epithelial keratopathy. Arch Ophthalmol. 1966;76:664–667.
- Erdinç C, Muhammet DO, Yusuf CY, et al. The ocular surface side effects of an anti-psychotic drug, clozapine. Cutan Ocul Toxicol. 2016;35:62–66.
- Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J. 1964;90:663–665.
- Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with chlozapine. Med J Aust. 2009;190:210–211.
- Ritch R, Krupin T, Henry C, et al. Oral imipramine and acute angle closure glaucoma. Arch Ophthalmol. 1994;112:67–68.
- Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs. 2004;18:475–484.
- Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26:749–767.
- Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 2001;119:1721–1723.
- El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.
- Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154:302–318.
- Schönhöfer PS, Werner B, Tröger U. Ocular damage associated with proton pump inhibitors. BMJ. 1997;314:1805.
- GLA Rodríguez, Mannino S, Wallander MA. Ocular safety of antiulcer drugs. Lancet. 1995;345:1059–1060.
- Makunts T, Alpatty S, Lee KC, et al. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Sci Rep. 2019;9:17280.
- Chronic pain in Australia. Australian Institute of Health and Welfare, 2020. Available from: https://www.aihw.gov.au/getmedia/10434b6f-2147-46ab-b654-a90f05592d35/aihw-phe-267.pdf.aspx?inline=true
- Nicastro NJ. Visual disturbances associated with over-the-counter ibuprofen in three patients. Ann Ophthalmol. 1989;21:447–450.
- Hamburger HA, Beckman H, Thompson R. Visual evoked potentials and ibuprofen (Motrin) toxicity. Ann Ophthalmol. 1984;16:328–329.
- Collum LM, Bowen D. Ocular side-effects of ibuprofen. Br J Ophthalmol. 1971;55:472–477.
- Gamulescu MA, Schalke B, Schuierer G, et al. Optic neuritis with visual field defect- possible Ibuprofen-related toxicity. Ann Pharmacother. 2006;40:571–573.
- Asherov J, Schoenberg A, Weinberger A. Diplopia following ibuprofen administration. JAMA. 1982;248:649.
- Palmer C. Toxic amblyopia from ibuprofen. Br Med J. 1972;3:765.
- Mohamed N, Meyer D. Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties. Clin Ophthalmol. 2013;7:219–227.
- Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31:127–141.